# entry[].resource.title
Randomized clinical trial conducted in India with 125 participants with chronic migraine. The study evaluated whether greater occipital nerve block, combined with topiramate, helped reduce monthly headache days. The treatment groups showed significant improvement, especially in achieving at least a 50% reduction in headache days by the third month.

# entry[].resource.relatedArtifact[].display
Debashish Chowdhury et al. Cephalalgia (SAGE Publications), 08 / 2022

# entry[].resource.relatedArtifact[].document.title
Efficacy and tolerability of combination treatment of topiramate and greater occipital nerve block versus topiramate monotherapy for the preventive treatment of chronic migraine: A randomized controlled trial

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes the placebo comparator used in a study evaluating Topamax for Migraine.

# entry[].resource.relatedArtifact[].display
Debashish Chowdhury et al. Cephalalgia (SAGE Publications), 08 / 2022

# entry[].resource.relatedArtifact[].document.title
Efficacy and tolerability of combination treatment of topiramate and greater occipital nerve block versus topiramate monotherapy for the preventive treatment of chronic migraine: A randomized controlled trial

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the placebo comparator divided by the number of people who received the placebo comparator. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on participants who achieved a persistent reduction in the intensity, frequency, or variety of symptoms in the placebo comparator group.

# entry[].resource.title
This Evidence resource describes the efficacy of placebo, from a systematic review evaluating acupuncture for the prevention of episodic migraine.

# entry[].resource.relatedArtifact[].display
Klaus Linde et al. Cochrane Database of Systematic Reviews, 06 / 2016

# entry[].resource.relatedArtifact[].document.title
Acupuncture for the prevention of episodic migraine

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a positive outcome when using the placebo as a preventive measure against the disease.

# entry[].resource.title
This Evidence resource describes a systematic review evaluating acupuncture for the prevention of episodic migraine.

# entry[].resource.relatesTo[].note
Klaus Linde et al. Cochrane Database of Systematic Reviews, 06 / 2016

# entry[].resource.relatesTo[].target.assertion
Acupuncture for the prevention of episodic migraine

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a positive outcome when using the treatment as a preventive measure against the disease.

# entry[].resource.title
This Evidence resource describes a systematic review evaluating acupuncture for the prevention of episodic migraine.

# entry[].resource.description
Klaus Linde et al. Cochrane Database of Systematic Reviews, 06 / 2016

# entry[].resource.assertion
Acupuncture for the prevention of episodic migraine

# entry[].resource.note[].text
Klaus Linde et al. Cochrane Database of Systematic Reviews, 06 / 2016

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a positive outcome when using the treatment as a preventive measure against the disease.

# entry[].resource.title
This Evidence resource describes a systematic review evaluating acupuncture for the prevention of episodic migraine.

# entry[].resource.description
Klaus Linde et al. Cochrane Database of Systematic Reviews, 06 / 2016

# entry[].resource.assertion
Acupuncture for the prevention of episodic migraine

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a positive outcome when using the treatment as a preventive measure against the disease.

# entry[].resource.title
Effect on fatal ICH comparing alteplase vs. placebo 3-4.5 hours after stroke

# entry[].resource.citeAs
Effect on fatal ICH comparing alteplase vs. placebo 3-4.5 hours after stroke [Database Entry: FHIR Evidence Resource]. Contributors: Brian S. Alper, MD, MSPH [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 560158. Revised 2026-04-13. Available at: https://fevir.net/resources/Evidence/560158. Computable resource at: https://fevir.net/resources/Evidence/560158#json.

# entry[].resource.relatesTo[].targetReference.display
25106063 Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.

# entry[].resource.variableDefinition[].intended.display
Patients treated 3-4.5 hours after acute stroke

# entry[].resource.variableDefinition[].description
Patients treated within 0-3 hours after acute stroke

# entry[].resource.variableDefinition[].intended.display
GroupAssignment: Alteplase vs. no alteplase (3-4.5 hours after stroke)

# entry[].resource.title
Effect on fatal ICH comparing alteplase vs. placebo 3-4.5 hours after stroke

# entry[].resource.citeAs
Effect on fatal ICH comparing alteplase vs. placebo 3-4.5 hours after stroke [Database Entry: FHIR Evidence Resource]. Contributors: Brian S. Alper, MD, MSPH [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 566434. Revised 2026-05-17. Available at: https://fevir.net/resources/Evidence/566434. Computable resource at: https://fevir.net/resources/Evidence/566434#json.

# entry[].resource.variableDefinition[].intended.display
Patients treated 3-4.5 hours after acute stroke

# entry[].resource.variableDefinition[].description
Patients treated within 0-3 hours after acute stroke

# entry[].resource.variableDefinition[].intended.display
GroupAssignment: Alteplase vs. no alteplase (3-4.5 hours after stroke)

# entry[].resource.title
Effect on fatal ICH comparing alteplase vs. placebo 3-4.5 hours after stroke

# entry[].resource.citeAs
Effect on fatal ICH comparing alteplase vs. placebo 3-4.5 hours after stroke [Database Entry: FHIR Evidence Resource]. Contributors: Brian S. Alper, MD, MSPH [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 566434. Revised 2026-05-17. Available at: https://fevir.net/resources/Evidence/566434. Computable resource at: https://fevir.net/resources/Evidence/566434#json.

# entry[].resource.variableDefinition[].intended.display
Patients treated 3-4.5 hours after acute stroke

# entry[].resource.variableDefinition[].description
Patients treated within 0-3 hours after acute stroke

# entry[].resource.variableDefinition[].intended.display
GroupAssignment: Alteplase vs. no alteplase (3-4.5 hours after stroke)

# entry[].resource.title
This Evidence resource describes a systematic review evaluating acupuncture for the prevention of episodic migraine.

# entry[].resource.description
Klaus Linde et al. Cochrane Database of Systematic Reviews, 06 / 2016

# entry[].resource.assertion
Acupuncture for the prevention of episodic migraine

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a positive outcome when using the treatment as a preventive measure against the disease.

# entry[].resource.title
This Evidence resource describes the placebo comparator used in a study evaluating acupuncture for the prevention of episodic migraine.

# entry[].resource.description
Klaus Linde et al. Cochrane Database of Systematic Reviews, 06 / 2016

# entry[].resource.assertion
Placebo comparator for acupuncture in the prevention of episodic migraine

# entry[].resource.statistic[].description
Efficacy calculated based on participants who achieved at least a 50% reduction in headache frequency in the sham acupuncture comparator group.

# entry[].resource.description
Test Evidence resource for R6 validation.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.